Industry Roadmap 4
Significant results typically develop over 3-6 months of consistent treatment
This triggers the release of key satiety hormones including GLP-1, CCK and PYY, which work together to significantly reduce hunger, cravings, and caloric intake
Surgeons should consider how the timing of elective procedures might shift if GLP-1 therapy is inducing substantial weight loss or anatomical change, which is relevant for bariatric, abdominal or head and neck surgeries
Ipamorelin is studied for its selective binding to ghrelin receptors, promoting growth hormone secretion without significant effect on other hormones like cortisol or prolactin
Apr 2, 2026 What if the real reason your GLP-1 results have stalled is not your dose, your timing, or your genetics